Literature DB >> 7880722

Loss of heterozygosity of the oestrogen receptor gene in breast cancer.

H Iwase1, J M Greenman, D M Barnes, L Bobrow, S Hodgson, C G Mathew.   

Abstract

DNA from 67 primary breast carcinoma biopsies has been examined for loss of heterozygosity (LOH) using the microsatellite (TA)n repeat marker positioned 1 kb upstream of the oestrogen receptor (ER) gene. Forty-seven (70.1%) of the cases were informative; nine of these (19.1%) were positive for LOH. In three of the nine cases, there was total loss, and in the other six cases there was a marked reduction in the intensity of signal from one allele. LOH correlated weakly with histological grade and age, but not with ER status. This result suggests that LOH of the ER gene does not have an important role in the lack of ER function in breast cancer tissues.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7880722      PMCID： PMC2033633          DOI： 10.1038/bjc.1995.91

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  23 in total

1.  Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique.

Authors:  L P Menasce; G R White; C J Harrison; J M Boyle
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

Review 2.  Microsatellite polymorphisms and the genetic linkage map of the human genome.

Authors:  J Weissenbach
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

3.  The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain.

Authors:  S A Fuqua; D C Allred; R M Elledge; S L Krieg; M G Benedix; Z Nawaz; B W O'Malley; G L Greene; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.

Authors:  T I Andersen; A Gaustad; L Ottestad; G W Farrants; J M Nesland; K M Tveit; A L Børresen
Journal:  Genes Chromosomes Cancer       Date:  1992-03       Impact factor: 5.006

5.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

6.  Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer.

Authors:  I Bièche; M H Champème; F Matifas; K Hacène; R Callahan; R Lidereau
Journal:  Lancet       Date:  1992-01-18       Impact factor: 79.321

7.  Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer.

Authors:  P G Knyazev; E N Imyanitov; O I Chernitsa; I F Nikiforova
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

8.  Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene.

Authors:  L del Senno; G L Aguiari; R Piva
Journal:  Hum Mol Genet       Date:  1992-08       Impact factor: 6.150

9.  Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines.

Authors:  U Pfeffer; E Fecarotta; L Castagnetta; G Vidali
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

Review 10.  Role of estrogen receptor variants in the development of hormone resistance in breast cancer.

Authors:  M Sluyser
Journal:  Clin Biochem       Date:  1992-12       Impact factor: 3.281
View more
  7 in total

Review 1.  The loss of estrogen and progesterone receptor gene expression in human breast cancer.

Authors:  R G Lapidus; S J Nass; N E Davidson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

2.  Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas.

Authors:  S A Chappell; T Walsh; R A Walker; J A Shaw
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers.

Authors:  H Iwase; Y Omoto; H Iwata; T Toyama; Y Hara; Y Ando; Y Ito; Y Fujii; S Kobayashi
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

4.  The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer.

Authors:  J-W Bai; M-N Chen; X-L Wei; Y-Ch Li; H-Y Lin; M Chen; J-W Li; C-W Du; K Man; G-J Zhang
Journal:  Oncogenesis       Date:  2017-05-08       Impact factor: 7.485

5.  Mapping of target regions of allelic loss in primary breast cancers to 1-cM intervals on genomic contigs at 6q21 and 6q25.3.

Authors:  Y Utada; S Haga; T Kajiwara; F Kasumi; G Sakamoto; Y Nakamura; M Emi
Journal:  Jpn J Cancer Res       Date:  2000-03

6.  Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy.

Authors:  Jason I Griffiths; Jinfeng Chen; Patrick A Cosgrove; Anne O'Dea; Priyanka Sharma; Cynthia Ma; Meghna Trivedi; Kevin Kalinsky; Kari B Wisinski; Ruth O'Regan; Issam Makhoul; Laura M Spring; Aditya Bardia; Frederick R Adler; Adam L Cohen; Jeffrey T Chang; Qamar J Khan; Andrea H Bild
Journal:  Nat Cancer       Date:  2021-06-03

Review 7.  Exploring new pathways in endocrine-resistant breast cancer.

Authors:  Inês Soares de Pinho; Catarina Abreu; Inês Gomes; Sandra Casimiro; Teresa Raquel Pacheco; Rita Teixeira de Sousa; Luís Costa
Journal:  Explor Target Antitumor Ther       Date:  2022-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.